Entrada Therapeutics Target Price

See Entrada Therapeutics's analyst price targets ($14) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.67

Average Target Price

$13.50

76% upside

2 analysts in the last 4 months

High: $17 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-06-08	Guggenheim	$17	121.6% upside
2026-05-08	Roth Capital	$10	30.4% upside
2026-02-10	Guggenheim	$20	160.8% upside
2026-01-28	OppenheimerKostas Biliouris	$21	173.8% upside
2025-11-06	Roth Capital	$13	69.5% upside
2025-02-28	Roth Capital	$23	199.9% upside
2024-11-06	H.C. WainwrightBoobalan Pachaiyappan	$20	160.8% upside
2024-06-25	H.C. WainwrightRaghuram Selvaraju	$18	134.7% upside

Entrada Therapeutics (TRDA) FAQ

The latest target price for TRDA is $14. Investors often review this figure alongside Entrada Therapeutics's historical trend and sector peers before judging valuation or financial health.

Entrada Therapeutics trades near $7.67 while the consensus target sits at $14 (76.0% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting TRDA's target price ($14), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.